03.02.26 -- An Anthropological Lens On Leadership In Life Sciences With Bunka's Monika Sumra, Ph.D.

When it comes to furthering AAV's potential in the wider biopharmaceutical pipeline, partnering with a CDMO that can foment an optimal analytical and manufacturing strategy is crucial.

Learn how expert site initiation visit (SIV) planning masters complex endpoints like OCT and BCVA, eliminates data variability, and prevents the costly need for trial rescue.

By operationalizing the early-phase strategies discussed in this article, trial teams can ensure that foundational safety and efficacy data are captured without the delays that derail studies.

Explore ERP readiness for life sciences, why QuickBooks falls short, how ERP supports compliance, the key third‑party tools for scaling, and what to seek in a strong implementation partner.

To truly maximize enrollment in decentralized models, sponsors must invest in human connection to build the trust needed to move patients from awareness to active participation.

The EU HTA regulation's first year reveals progress in harmonizing assessments alongside challenges in PICO consolidation, resource constraints, and patient engagement that require strategic adaptation.